NYSE:SQZ - New York Stock Exchange, Inc. - US78472W1045 - Common Stock - Currency: USD
0.435
+0.16 (+61.11%)
The current stock price of SQZ is 0.435 USD. In the past month the price decreased by -27.5%. In the past year, price decreased by -87.5%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.26 | 362.28B | ||
AMGN | AMGEN INC | 15.63 | 166.37B | ||
GILD | GILEAD SCIENCES INC | 24.19 | 138.93B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1663.07 | 123.90B | ||
REGN | REGENERON PHARMACEUTICALS | 15.57 | 77.69B | ||
ARGX | ARGENX SE - ADR | N/A | 38.54B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.45B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.09B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.70B | ||
NTRA | NATERA INC | N/A | 21.35B | ||
BIIB | BIOGEN INC | 8.54 | 20.50B | ||
UTHR | UNITED THERAPEUTICS CORP | 15.91 | 16.17B |
SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. The company is headquartered in Watertown, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2020-10-30. The firm is focused on unlocking the full potential of cell therapies to benefit patients. In oncology, it is developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. Its clinical-stage cell therapy candidates include SQZ Enhanced APC (eAPC) Platform, SQZ Activating Antigen Carrier (AAC) Platform and SQZ Tolerizing Antigen Carrier (TAC) Platform. The SQZ eAPC platform is the second-generation product candidate designed to generate tumor specific CD8+ T cell activation to drive the antitumor immune response. The SQZ AAC platform is designed to induce antigen presentation in vivo by deriving antigen carriers from engineering red blood cells (RBCs) with tumor specific antigens and adjuvants. Its SQZ TAC platform is designed to induce antigen-specific immune tolerance in vivo by utilizing a similar approach to the AAC platform.
SQZ BIOTECHNOLOGIES CO
200 Arsenal Yards Blvd, Suite 210
Watertown MASSACHUSETTS 02472 US
CEO: Armon Sharei
Employees: 53
Company Website: https://sqzbiotech.com/
Phone: 16177588672.0
The current stock price of SQZ is 0.435 USD. The price increased by 61.11% in the last trading session.
The exchange symbol of SQZ BIOTECHNOLOGIES CO is SQZ and it is listed on the New York Stock Exchange, Inc. exchange.
SQZ stock is listed on the New York Stock Exchange, Inc. exchange.
6 analysts have analysed SQZ and the average price target is 19.38 USD. This implies a price increase of 4355.17% is expected in the next year compared to the current price of 0.435. Check the SQZ BIOTECHNOLOGIES CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SQZ BIOTECHNOLOGIES CO (SQZ) has a market capitalization of 12.83M USD. This makes SQZ a Nano Cap stock.
SQZ BIOTECHNOLOGIES CO (SQZ) currently has 53 employees.
SQZ BIOTECHNOLOGIES CO (SQZ) has a resistance level at 0.52. Check the full technical report for a detailed analysis of SQZ support and resistance levels.
The Revenue of SQZ BIOTECHNOLOGIES CO (SQZ) is expected to grow by 65.7% in the next year. Check the estimates tab for more information on the SQZ EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SQZ does not pay a dividend.
SQZ BIOTECHNOLOGIES CO (SQZ) will report earnings on 2023-08-02, after the market close.
SQZ BIOTECHNOLOGIES CO (SQZ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.45).
ChartMill assigns a fundamental rating of 3 / 10 to SQZ. The financial health of SQZ is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months SQZ reported a non-GAAP Earnings per Share(EPS) of -2.45. The EPS increased by 7.89% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 77% to SQZ. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 19.72% and a revenue growth 65.7% for SQZ